3/20
07:42 pm
vrca
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
High
Report
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
3/20
09:09 am
vrca
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
Medium
Report
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
3/19
02:15 pm
vrca
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
Low
Report
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
3/11
08:32 am
vrca
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
High
Report
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/11
08:00 am
vrca
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
High
Report
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
3/11
07:19 am
vrca
Verrica Pharmaceuticals (VRCA) was downgraded by Zacks Research from "strong-buy" to "hold".
Low
Report
Verrica Pharmaceuticals (VRCA) was downgraded by Zacks Research from "strong-buy" to "hold".
3/5
08:00 am
vrca
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
Low
Report
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
2/23
08:13 am
vrca
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/23
08:00 am
vrca
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Low
Report
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
2/12
08:00 am
vrca
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
Medium
Report
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
2/9
08:00 am
vrca
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
Medium
Report
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
2/7
02:07 am
vrca
Verrica Pharmaceuticals (NASDAQ:VRCA) was downgraded by analysts at
Wall
Medium
Report
Verrica Pharmaceuticals (NASDAQ:VRCA) was downgraded by analysts at
Wall
1/17
01:11 am
vrca
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at
Wall S
Medium
Report
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at
Wall S
1/13
05:44 am
vrca
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/7
05:01 pm
vrca
Verrica Pharmaceuticals (NASDAQ:VRCA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Verrica Pharmaceuticals (NASDAQ:VRCA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/7
08:00 am
vrca
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Low
Report
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts